The European Journal of Health Economics

2002 - 2025

Current editor(s): J.-M.G.v.d. Schulenburg

From:
Springer
Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ)
Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 7, issue 4, 2006

Time for a common standard for cost-effectiveness in Europe? pp. 223-224

Bengt Jönsson

Optional deductibles in social health insurance systems pp. 225-230

Claudia Pütz and Christian Hagist

A decomposition of income-related health inequality applied to EQ-5D pp. 231-237

Jens Gundgaard and Jørgen Lauridsen

Cost effectiveness of preventive home visits to the elderly pp. 238-246

Christian Kronborg, Mikkel Vass, Jørgen Lauridsen and Kirsten Avlund

Cost-benefit analysis of a plant sterol containing low-fat margarine for cholesterol reduction pp. 247-254

A. Gerber, T. Evers, H. Haverkamp and K. Lauterbach

Cost-effectiveness of the Danish smoking cessation interventions pp. 255-264

Kim Olsen, Lone Bilde, Henrik Juhl, Niels Kjaer, Holger Mosbech, Torben Evald, Mette Rasmussen and Helle Hiladakis

The demand for private health care under national health insurance pp. 265-269

Y. Machnes

Economic cost associated with type II diabetes in Spanish patients pp. 270-275

Miguel Ballesta, Florentino Carral, Gabriel Olveira, José Girón and Manuel Aguilar

Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany pp. 276-284

Alan Brennan, Roberta Ara, Raimund Sterz, Bernd Matiba and Rito Bergemann

Tests of stationarity and cointegration of health care expenditure and gross domestic product pp. 285-289

Halil Kiymaz, Yasemin Akbulut and Ahmet Demir

Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany pp. 290-296

W. Greiner, K. Lehmann, S. Earnshaw, C. Bug and R. Sabatowski

Volume 7, issue 3, 2006

Risk-sharing agreements for innovative drugs pp. 155-157

Gérard Pouvourville

Nonmedical economic consequences attributable to visual impairment pp. 158-164

Antoine Lafuma, Antoine Brezin, Francis Fagnani, Viviane Mimaud, Mounir Mesbah and Gilles Berdeaux

A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany pp. 165-172

Stephen Beard, Fiona Maciver, Johannes Clouth and Eckart Rüther

Test-retest reliability of willingness to pay pp. 173-178

Alan Shiell and Penelope Hawe

The costs of schizophrenia in Spain pp. 179-184

Juan Oliva, Julio López-Bastida, Ruben Osuna, Angel Montejo-González and Beatriz Duque-González

Health care in the CIS countries pp. 185-191

Anatoly Pilyavsky and Matthias Staat

Problems and costs associated with alcohol and drug abuse in emergency medicine pp. 192-194

F.-X. Huber, T. Hackert and P. Meeder

Determinants of household health expenditure on western institutional health care pp. 195-203

Tin Su, Subhash Pokhrel, Adjima Gbangou and Steffen Flessa

Price regulation and generic competition in the pharmaceutical market pp. 204-211

Dag Dalen, Steinar Strøm and Tonje Haabeth

Alcohol-related mortality, drinking behavior, and business cycles pp. 212-217

Edvard Johansson, Petri Böckerman, Ritva Prättälä and Antti Uutela

Decision models in the evaluation of psychotropic drugs pp. 218-220

Corrado Barbui and Camilla Lintas

Volume 7, issue 2, 2006

Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis pp. 5-13

Gisela Kobelt, Jenny Berg, Peter Lindgren and Bengt Jönsson

Costs and quality of life of multiple sclerosis in Austria pp. 14-23

Gisela Kobelt, Jenny Berg, Peter Lindgren, Carlotta Plesnilla, Ulf Baumhackl, Thomas Berger, Harald Kolleger and Karl Vass

Costs and quality of life for patients with multiple sclerosis in Belgium pp. 24-33

Gisela Kobelt

Costs and quality of life of multiple sclerosis in Germany pp. 34-44

Gisela Kobelt, Jenny Berg, Peter Lindgren, W. Elias, P. Flachenecker, M. Freidel, N. König, V. Limmroth and E. Straube

Costs and quality of life of multiple sclerosis in Italy pp. 45-54

Gisela Kobelt, Jenny Berg, Peter Lindgren, M. Battaglia, C. Lucioni and A. Uccelli

Costs and quality of life in multiple sclerosis in The Netherlands pp. 55-64

Gisela Kobelt, J. Berg and P. Lindgren

Costs and quality of life of multiple sclerosis in Spain pp. 65-74

Gisela Kobelt, J. Berg, P. Lindgren, G. Izquierdo, O. Sánchez-Soliño, J. Pérez-Miranda and M. Casado

Costs and quality of life of multiple sclerosis in Sweden pp. 75-85

Jenny Berg, P. Lindgren, Sten Fredrikson and Gisela Kobelt

Costs and quality of life of multiple sclerosis in Switzerland pp. 86-95

Gisela Kobelt, Jenny Berg, Peter Lindgren, Andrea Gerfin and J. Lutz

Pharmaceutical policy in Italy pp. 89-90

Livio Garattini and Dante Cornago

The reasons of general practitioners for promoting colorectal cancer mass screening in France pp. 91-98

Célia Berchi, Jean-Marc Dupuis and Guy Launoy

Costs and quality of life of multiple sclerosis in the United Kingdom pp. 96-104

Gisela Kobelt, Jenny Berg, P. Lindgren, J. Kerrigan, N. Russell and R. Nixon

Choices and utilization in dental care pp. 99-106

Lien Nguyen and Unto Häkkinen

Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer pp. 107-113

Samuel Limat, Claire-Hélène Bracco-Nolin, Christine Legat-Fagnoni, Loic Chaigneau, Ulrich Stein, Bernard Huchet, Xavier Pivot and Marie-Christine Woronoff-Lemsi

Health care and patients’ migration across Spanish regions pp. 114-116

David Cantarero

The future of imaging techniques for cancer patients in The Netherlands pp. 117-122

Theo Postma, Janneke Alers, Sijmon Terpstra and Arjan Zuurbier

Factors influencing the costs of emergency medical admissions to an Irish teaching hospital pp. 123-128

Edward Moloney, Kathleen Bennett and Bernard Silke

Outcomes research collaborations between third-party payers, academia, and pharmaceutical manufacturers pp. 129-136

Hans-Georg Eichler, Sheldon Kong and Jean-Pierre Grégoire

Cost-effectiveness of memantine in community-based Alzheimer’s disease patients: an adaptation in Spain pp. 137-144

Fernando Antonanzas, Benoit Rive, Josep Badenas, Susana Gomez-Lus and Chantal Guilhaume

Costs of chemotherapy in the treatment of colorectal cancer pp. 145-146

F. Jansman and M. Postma

A taxonomy of health utility assessment methods and the role for uncertainty analysis pp. 147-151

Agota Szende and Caroline Schaefer

Volume 7, issue 02, 2006

Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis pp. 5-13

Gisela Kobelt, Jenny Berg, Peter Lindgren and Bengt Jönsson

Costs and quality of life of multiple sclerosis in Austria pp. 14-23

Gisela Kobelt, Jenny Berg, Peter Lindgren, Carlotta Plesnilla, Ulf Baumhackl, Thomas Berger, Harald Kolleger and Karl Vass

Costs and quality of life for patients with multiple sclerosis in Belgium pp. 24-33

Gisela Kobelt

Costs and quality of life of multiple sclerosis in Germany pp. 34-44

Gisela Kobelt, Jenny Berg, Peter Lindgren, W. Elias, P. Flachenecker, M. Freidel, N. König, V. Limmroth and E. Straube

Costs and quality of life of multiple sclerosis in Italy pp. 45-54

Gisela Kobelt, Jenny Berg, Peter Lindgren, M. Battaglia, C. Lucioni and A. Uccelli

Costs and quality of life in multiple sclerosis in The Netherlands pp. 55-64

Gisela Kobelt, J. Berg and P. Lindgren

Costs and quality of life of multiple sclerosis in Spain pp. 65-74

Gisela Kobelt, J. Berg, P. Lindgren, G. Izquierdo, O. Sánchez-Soliño, J. Pérez-Miranda and M. Casado

Costs and quality of life of multiple sclerosis in Sweden pp. 75-85

Jenny Berg, P. Lindgren, Sten Fredrikson and Gisela Kobelt

Costs and quality of life of multiple sclerosis in Switzerland pp. 86-95

Gisela Kobelt, Jenny Berg, Peter Lindgren, Andrea Gerfin and J. Lutz

Costs and quality of life of multiple sclerosis in the United Kingdom pp. 96-104

Gisela Kobelt, Jenny Berg, P. Lindgren, J. Kerrigan, N. Russell and R. Nixon

Volume 7, issue 1, 2006

The desirability and feasibility of economic studies of drugs post-launch pp. 5-6

Michael Drummond, Anne Mason and Adrian Towse

The relationship between health care expenditure and health outcomes pp. 7-18

John Nixon and Philippe Ulmann

Pharmacoeconomic modelling in schizophrenia pp. 19-29

Karina Hansen, Christophe Lançon and Mondher Toumi

Comparing costs and effectiveness of different starting points for highly active antiretroviral therapy in HIV-positive patients pp. 30-36

Monica Merito and Patrizio Pezzotti

Fixed budgets as a cost containment measure for pharmaceuticals pp. 37-45

David Granlund, Niklas Rudholm and Magnus Wikström

The Danish effect on Swedish alcohol costs pp. 46-54

Johan Jarl, Ulf-G. Gerdtham, Carl Hampus Lyttkens, Thor Lithman and Juan Merlo

Prospective casemix-based funding, analysis and financial impact of cost outliers in all-patient refined diagnosis related groups in three Belgian general hospitals pp. 55-65

Magali Pirson, Dimitri Martins, Terri Jackson, Michèle Dramaix and Pol Leclercq

Case-control analysis of the financial cost of medication errors in hospitalized patients pp. 66-71

Jaime Pinilla, Carles Murillo, Genís Carrasco and Carlos Humet

Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care pp. 72-78

Steven Edwards, Helen Campbell and Jonathan Plumb

Off-patent drugs in Italy pp. 79-83

Livio Garattini and Simone Ghislandi